TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00617513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 1 mg o.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 2 mg o.d.
Study: NCT02427802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin collagen sponge
Description: Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching collagen sponge
Study: NCT01081405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TOTAL LYMPHOID IRRADIATION
Description: Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies
Study: NCT04622072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XZP-5809-TT1 Tablet
Description: Single tartrate of XZP-5809
Study: NCT02254057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBT 986 BS - single rising dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02249013

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Surgery (CRS)
Description: CRS was performed with standard peritonectomy procedures and visceral resections directed towards complete elimination of tumors from the abdominopelvic cavity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Description: HIPEC was performed according to the closed-abdomen technique using CDDP (25 mg/L of perfusate/m2, total limit of 240mg) for the first 10 patients and thus, using CDDP plus Doxorubicin (15mg/L) thereafter, both for 30 minutes, with an intra-abdominal target temperature of 41-43°C. Perfusate (2L/m2, ranging from 4L to 6L) was circulated using an extracorporeal circulation device (Performer HT; RAND, Medolla, Italy) at a flow rate of 700 ml/min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy (NACT)
Description: Systemic chemotherapy included the standard combination of carboplatin (AUC 6) and paclitaxel (175 mg/m2) administered every 21 days as neoadjuvant (2-4 cycles) plus adjuvant regimens (2-4 cycles), in the total of 6 cycles of systemic chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Chemotherapy
Description: Systemic chemotherapy included the standard combination of carboplatin (AUC 6) and paclitaxel (175 mg/m2) administered every 21 days as neoadjuvant (2-4 cycles) plus adjuvant regimens (2-4 cycles), in the total of 6 cycles of systemic chemotherapy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fast-track recovery strategy
Description: A comprehensive fast-track program was applied to accelerate recovery, reduce morbidity, and shorten convalescence for patients enrolled in our trial.
Study: NCT01048086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retinoic Acid
Description: 160 mg, given orally, divided BID on Days 1-4 of each cycle for 4 cycles. Each cycle will be six weeks in duration. Dose will be adjusted to 5.33 mg/kg/day divided BID for children \<12 kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given in the same manner as retinoic acid in capsules that look identical.
Study: NCT04559425

Intervention type: DRUG
Intervention: Dexamethasone
Description: All management decisions are made by the primary physician and may include: 1) no treatment with dexamethasone or 2) treatment with dexamethasone from the time of enrollment

Intervention type: DRUG
Intervention: Dexamethasone
Description: All management decisions are made by the primary physician and may include: 1) no treatment with dexamethasone or 2) treatment with dexamethasone from the time of enrollment

Intervention type: OTHER
Intervention: No Dexamethasone
Description: All management decisions are made by the primary physician and may include: 1) no treatment with dexamethasone or 2) treatment with dexamethasone from the time of enrollment

Intervention type: OTHER
Intervention: No Dexamethasone
Description: All management decisions are made by the primary physician and may include: 1) no treatment with dexamethasone or 2) treatment with dexamethasone from the time of enrollment
Study: NCT05535322

Intervention type: DRUG
Intervention: GLP-1RA
Description: All T2D adults treated with Glucagon-like peptide-1 receptor agonists (GLP-1RA) or initiating a GLP-1RA during the study period

Intervention type: DRUG
Intervention: SGLT2i
Description: SGLT2 inhibitors users with no GLP-1RA prescription: all T2D adults treated with Sodium/glucose cotransporter-2 inhibitors (SGLT2i) or initiating treatment with SGLT2i during the study period and who were not treated with a GLP-1RA

Intervention type: DRUG
Intervention: Insulin
Description: Insulin users with no GLP-1RA and/or SGLT2i prescriptions: all T2D adults treated with insulin or initiating insulin treatment during the study period and who were not treated with GLP-1RA/SGLT2i

Intervention type: DRUG
Intervention: Miscellany
Description: Other glucose-lowering agents users: all T2D adults who were not treated with GLP-1RA and/or SGLT2i and/or insulin during the study period and who were treated with other glucose-lowering agents during the study period
Study: NCT04166292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stylage® XL Lidocaïne
Description: On V1 (D0), a total volume of 8 mL maximum can be used per subject on the whole face.~On V2 (M1), a possible touch-up can be made according to the injector and subject's opinion which cannot exceed 4 ml.
Study: NCT02215499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Oxybate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JZP-386
Study: NCT03922607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-157
Description: ABBV-157 will be administered orally as capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-157
Description: ABBV-157 will be administered orally as capsule
Study: NCT03922607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-157
Description: ABBV-157 will be administered orally as capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-157
Description: ABBV-157 will be administered orally as capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-157
Description: ABBV-157 will be administered orally as capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-157
Description: Placebo for ABBV-157 will be administered orally as capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-157
Description: Placebo for ABBV-157 will be administered orally as capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-157
Description: Placebo for ABBV-157 will be administered orally as capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-157
Description: Placebo for ABBV-157 will be administered orally as capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-157
Description: Placebo for ABBV-157 will be administered orally as capsule
Study: NCT01388062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrosensing antibody probing system (e- Ab sensor)
Description: Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti- influenza virus antibody and its antigen (influenza virus) present in patients. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (influenza virus) in the test specimens. From assessment of the electric signature of semiconductive anti- influenza virus antibodies, the eABprobe could offer sensitive detection and precise quantification of EV71.
Study: NCT01189422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teplizumab or placebo
Description: infusion or injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teplizumab or placebo
Description: infusion or injection
Study: NCT04216485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention
Description: Dietary intervention combined with healthy lifestyle counseling

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard prenatal care on diet, nutrition and physical activity
Study: NCT01486368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03446962
Description: PF-03446962 will be administered by IV infusion every 2 weeks (q2w). A cycle will be 2 weeks in duration and include one administration of PF-03446962.
Study: NCT01187745

Intervention type: OTHER
Intervention: CT Scan followed by ultrasound
Description: A limited U/S is performed after the CT scan which is ordered by the Emergency Department physician.
Study: NCT05294718

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal shunt
Description: glenn with internal shunt (veno-atrial shunt) where the surgeon established a shunt between distal SVC and the right atrium, Establishing a veno-atrial shunt.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External shunt
Description: Glenn with external shunt where the anesthesiologist connected the internal Jagular venous cannula which represent the SVC with the main lumen of the femoral cannula which represent the IVC through long venous extension
Study: NCT04699097

Intervention type: DRUG
Intervention: Azithromycin
Description: 250 mg tablet, 5 ml / 200 mg 30 ml suspension
Study: NCT02544958

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Description: Er:YAG laser treats enlarged pores on both sides of the face for 4 treatments of 1 month interval.
Study: NCT00951106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine/sulfdoxine (Fansidar)
Study: NCT01728207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMMU-114
Description: hL243 is a humanized antibody that targets HLA-DR, which is found on various b-cell hematologic malignancies and in autoimmune diseases.
Study: NCT02338427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proteomic analysis
Study: NCT03028259

Intervention type: OTHER
Intervention: lab results
Description: Comparison of lab results
Study: NCT02673294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance virtual rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance virtual rehabilitation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance virtual rehabilitation
Study: NCT01560572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus OD, mycophenolic acid, prednisolone
Description: tacrolimus maintenance 6-10 ng/ml, in the low dose tacrolimus group after 6 months fixed dose reduction of 50% tacrolimus through levels will be 3-5 ng/ml mycophenolic acid 2 dd 720mg, after 2 weeks reduced to 2 dd 540 mg in all groups methylprednisolone 500, 250, 125 mg on day 0, 1, and 2 in all groups prednisolone 1 dd 10 mg, and from week 6 prednisolone 7.5 mg in the standard immunosuppression and low dose tacrolimus group No prednisolone will be given the steroid free group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus OD, mycophenolic acid, prednisolone
Description: tacrolimus maintenance 6-10 ng/ml, in the low dose tacrolimus group after 6 months fixed dose reduction of 50% tacrolimus through levels will be 3-5 ng/ml mycophenolic acid 2 dd 720mg, after 2 weeks reduced to 2 dd 540 mg in all groups methylprednisolone 500, 250, 125 mg on day 0, 1, and 2 in all groups prednisolone 1 dd 10 mg, and from week 6 prednisolone 7.5 mg in the standard immunosuppression and low dose tacrolimus group No prednisolone will be given the steroid free group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus OD, mycophenolic acid, prednisolone
Description: tacrolimus maintenance 6-10 ng/ml, in the low dose tacrolimus group after 6 months fixed dose reduction of 50% tacrolimus through levels will be 3-5 ng/ml mycophenolic acid 2 dd 720mg, after 2 weeks reduced to 2 dd 540 mg in all groups methylprednisolone 500, 250, 125 mg on day 0, 1, and 2 in all groups prednisolone 1 dd 10 mg, and from week 6 prednisolone 7.5 mg in the standard immunosuppression and low dose tacrolimus group No prednisolone will be given the steroid free group
Study: NCT04525131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-POM
Description: CPX-POM
Study: NCT02795936

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac rehabilitation
Description: Perform exercise prescription for 12 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac rehabilitation
Description: Perform exercise prescription for 12 weeks

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac rehabilitation
Description: Perform exercise prescription for 12 weeks
Study: NCT03295175

Intervention type: DIAGNOSTIC_TEST
Intervention: Hematoxylin-eosin and smooth muscle actin markers
Description: The foreskin arrives oriented in a single piece in formol to the unit of pathology, and in the pathology unit, they must:~1. Measure the length, width and thickness of the specimen. The specimen should include skin and mucosa with the underlying areolar tissue.~2. Examine the surfaces of the sample searching lesions, and describe them in size, appearance (warty, papillary, ulcerated), depth of invasion, and distance from the nearest cutting edge, if they are present.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hematoxylin-eosin and smooth muscle actin markers
Description: The foreskin arrives oriented in a single piece in formol to the unit of pathology, and in the pathology unit, they must:~1. Measure the length, width and thickness of the specimen. The specimen should include skin and mucosa with the underlying areolar tissue.~2. Examine the surfaces of the sample searching lesions, and describe them in size, appearance (warty, papillary, ulcerated), depth of invasion, and distance from the nearest cutting edge, if they are present.

Intervention type: DIAGNOSTIC_TEST
Intervention: Hematoxylin-eosin and smooth muscle actin markers
Description: The foreskin arrives oriented in a single piece in formol to the unit of pathology, and in the pathology unit, they must:~1. Measure the length, width and thickness of the specimen. The specimen should include skin and mucosa with the underlying areolar tissue.~2. Examine the surfaces of the sample searching lesions, and describe them in size, appearance (warty, papillary, ulcerated), depth of invasion, and distance from the nearest cutting edge, if they are present.
Study: NCT01665482

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A 2000 kcal test meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A 2000 kcal test meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A 2000 kcal test meal which accounts for 7% fat exchange with carbohydrate
Study: NCT04324515

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Robotic gastric bypass with or without cholecystectomy
Description: Study Arm: robotic gastric bypass without cholecystectomy Control Arm: robotic gastric bypass with cholecystectomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Robotic gastric bypass with or without cholecystectomy
Description: Study Arm: robotic gastric bypass without cholecystectomy Control Arm: robotic gastric bypass with cholecystectomy
Study: NCT02739451

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard oxygen
Description: Devices used to treat spontaneously ventilating patients in the ICU who require supplemental oxygen. They deliver either~* low-flow oxygen \[including nasal cannula, Ventimask® without Venturi effect, and non-rebreather mask\]~* or medium-flow oxygen \[Venturi masks and medium-flow facemasks\]

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HFNO
Description: The intervention is the use of a device that allows to deliver high flow humidified and warmed oxygen. The device used is the Optiflow™ (Fisher\&Paykel, Courtaboeuf, France).
Study: NCT01315652

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comorbidities treatment
Description:  Comorbidities treatment:Number of actions initiated in order to treat or prevent Rheumatoid Arthritis comorbidities during the 6 months follow-up

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auto-DAS
Description: Auto-DASNumber of patients with a modification in their treatment between baseline and 6 months visits
Study: NCT00511485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vintafolide
Description: Induction: vintafolide 1.0 mg intravenous injection, Monday through Friday, for the first 3 weeks of each 4 week cycle. Maintenance: vintafolide 2.5 mg intravenous injection, Monday, Wednesday, and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etarfolatide
Study: NCT03810235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal Lidocaine Patch
Description: Transdermal Lidocaine Patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Transdermal Hydrocolloid Placebo Patch
Description: hydrocolloid placebo patches
Study: NCT01308632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolamide, irinotecan
Description: Phase I trial:~TMZ will be administered in a fixed schedule as follows:~TMZ 50 mg/m2/day divided in three daily doses (approx. 17 mg/m2/8 hours) on days 1-7, 9-21, and 23-28.~100 mg/m2 in a morning single dose on days 8 and 22~CPT-11 starting dose:~100 mg/m2 on days 8 and 22, administered 3 to 6 hours after TMZ. (Level 1)~One cycle = 28 days~CPT-11 will be escalated in successive cohorts of 3 patients as follows: 115, 130, 145, 160 mg/m2 .
Study: NCT02443272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vessel Loop Drainage
Description: Minimally invasive approach will utilize a vesi-loop device for the vessel loop drainage technique by placing 2 peripheral stab incisions into the abscess with a tunnel through the abscess cavity, and loop passed through the tunnel and tied atop the skin.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision and Drainage
Description: Standard of care treatment will utilize incision and drainage over the center of the abscess cavity with or without packing at physicians discretion.
Study: NCT02811575

Intervention type: OTHER
Intervention: Biopsy
Description: Ileon and colon biopsy

Intervention type: OTHER
Intervention: Biopsy
Description: Ileon and colon biopsy
Study: NCT01016574

Intervention type: DEVICE
Group type: OTHER
Intervention: Support Device for Prone radiation therapy (Giro-Couch)
Description: Boost irradiation is applied to the ipsilateral breast in eight fractions of 2Gy/Fx
Study: NCT03845075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesofensine/Metoprolol
Description: During Part 1 subjects will be randomized to treatment with co-administration of 0.5 mg tesofensine/50mg metoprolol (active medication)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During Part 1 subjects will be randomized to matching placebo tesofensine and placebo metoprolol
Study: NCT03289299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 56 mg/m2 IV given on days 1, 8, and 15 of each cycle during induction and consolidation phases of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg po given on days 1-21 of each cycle during the induction and consolidation phases.~10 mg po given on days 1-21 of each cycle during the maintenance phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: 16 mg/kg IV given on days 1, 8, 15, and 22 of cycles 1-2; days 1 and 15 of cycles 3-6; day 1 of cycle 7-12; Day 1 of odd cycles for cycles 13-24.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg oral given on days 1, 8, 15, and 22 of cycles 1-6 20 mg oral given on days 1, 8, 15, and 22 of cycles 7-12
Study: NCT01325571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus capsule
Description: oral
Study: NCT01183715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05161704 or placebo
Description: PF-05161704 will be administered as an extemporaneously prepared suspension in the initially planned dose range of 1.5 mg to 300 mg. Correspondingly, placebo doses will be administered as suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05161704 or placebo
Description: PF-05161704 will be administered as an extemporaneously prepared suspension in the initially planned dose range of 1.5 mg to 300 mg. Correspondingly, placebo doses will be administered as suspension
Study: NCT01325571

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study: NCT04780243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling
Description: Mothers presented to infant immunization units are going to be counseled for family planning services and if decide to take any method, they will be linked to family planning services
Study: NCT02699476

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-Social Therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Computer Training

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Computer Training

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interactive Trainer-Subject Sessions
Study: NCT02798692

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Low dose HB-101
Description: Three intra muscular administrations at Day 0, Month 1 and Month 3

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Medium dose HB-101
Description: Three intra muscular administrations at Day 0, Month 1 and Month 3

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High dose HB-101
Description: Three intra muscular administrations at Day 0, Month 1 and Month 3

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three intra muscular administrations at Day 0, Month 1 and Month 3. The diluent is used as placebo.
Study: NCT02699476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive Trainer-Subject Sessions

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Games